pfizer glp-1 pipeline has released promising mid-stage Phase IIb trial data for its obesity treatment, PF-3944. This long-acting injectable demonstrated an impressive 12.3% placebo-adjusted weight loss at 28 weeks with monthly dosing, positioning Pfizer adds small molecule GLP-1
Pay in 4 interest-free payments of $5.08 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18

























